Recurring Candida albicans esophagitis in a HIV-infected patient undergoing long-term antiretroviral therapy, and with absent-negligible immunodeficiency

Brazilian Journal of Infectious Diseases

Volumn 11, Issue 6, 2007, Pages 605-609

  Manfredi, Roberto ^a   Sabbatani, Sergio ^a   Calza, Leonardo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiretroviral therapy; CD4+lymphocyte count; Esophageal candidiasis; HIV infection; HIV viral load; Negligible or absent immunodeficiency; Recurring opportunistic disease

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; LAMIVUDINE; NYSTATIN; STAVUDINE; TENOFOVIR;

ADULT; ARTICLE; CANDIDA ALBICANS; CASE REPORT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG SUBSTITUTION; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS CANDIDIASIS; FUNGAL STRAIN; HEPATITIS C; HIATUS HERNIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; LYMPHOCYTE COUNT; MALE; MALE HOMOSEXUAL; PATIENT COMPLIANCE; RECURRENT DISEASE; RELAPSE; VIREMIA; VIRUS LOAD;

EID: 41149094966     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702007000600016     Document Type: Article

References (38)

1. Mocroft A., Youle M., Phillips A.N., et al. The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Arch Intern Med 1998;158:491-7.
2. Manfredi R. Effects of the introduction of highly active antiretroviral therapy (HAART) on the temporal trend of diagnosis of AIDS and AIDS-defining disorders. Infez Med 2000;8:134-8.
3. Kaplan J.E., Hanson D., Dworkin M.S., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl. 1):S5-14.
4. Yazdanpanah T., Chene G., Losina E., et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol 2001;30:664-71.
5. Lyles R.H., Chu C., Mellors J.W., et al. Prognostic value of plasma HIV RNA in the natural history of Pneumocystis, carinii pneumonia, cytomegalovirus and Mycobacterium avium complex. Multicenter AIDS Cohort Study. AIDS 1999;13:341-9.
6. Manfredi R., Nanetti A., Mazzoni A., et al. The incidence, etiology, and clinical significance of visceral mycoses in patients with AIDS. Minerva Med 1993;84:383-91.
7. Naito Y., Yoshikawa T., Oyamada H., et al. Esophageal candidiasis. Gastroenterol Jpn 1988;23:363-70.
8. Knobber D., Brusis T. Clinical aspects of therapy of esophageal candidiasis. Laryngol Rhinol Otol (Stuttg) 1985;64:314-7.
9. Manfredi R., Calza L., Chiodo F. Lack of change in the distribution of AIDS-defining opportunistic diseases and the related degree of immunodeficiency during the periods before and after the introduction of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2001;20:410-3.
10. Suligoi B., Boros S., Camoni L., et al. Aggiornamento dei casi di AIDS notificati in Italia e delle nuove diagnosi di infezione da HIV. Centro Operativo AIDS, Istituto Superiore di Sanita, Rome, issued on December 2005:1-24.
11. Jing W., Ismail R. Mucocutaneous manifestations of HIV infection: a retrospective analysis of 145 cases in a Chinese population in Malaysia. Int J Dermatol 1999;38:457-63.
12. Smit C., Geskus R., Walker S., et al. CASCADE Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006;20:741-9.
13. Gona P., Van Dyke R.B., Williams P.L., et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006;296:292-300.
14. Cassone A., Tacconelli E., De Bernardis F., et al Antiretroviral therapy with protease inhibitors has an early immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis 2002; 185:188-95.
15. Manfredi R., Calza L., Chiodo F. AIDS-defining fungal opportunism in the HAART era. Trend of frequency and reduced incidence when HIV protease inhibitors are administered. Clin Microbiol Infect 2006;12(Suppl., 4):1226.
16. Baehr P.H., McDonald G.B. Esophageal infections: risk factors, presentation, diagnosis, and treatment. Gastroenterology 1994; 106:509-32.
17. Mastroianni A., Cancellieri C., Coronado O., et al. Bacterial esophagitis in patients with HIV disease. Infez Med 1999;7:192-4.
18. Simon M.R., Houser W.L., Smith K.A., Long P.M. Esophageal-candidiasis as a complication of inhaled corticosteroids. Ann Allergy Asthma Immunol 1997;79:333-8.
19. Gupta E., Vajpayee M., Xess I., Seth P. Oral candididasis in HIV-infected patients and its relation to CD4+ counts: an adjunct clinical markes of HIV disease progression. Trop Doct 2006;36:127.
20. Abgrall S., Charreau I., Joly V., et al. Delta Coordinating Committee. Risk factors for esophageal candidiasis in a large cohort of HIV-infected patients treated with nucleoside analogues. Eur J Clin Microbiol Infect Dis 2001;20:346-9.
21. Lilleri D., Piccinini G., Baldanti F., et al. Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response. J Clin Virol 2003;26:95-100.
22. Bonavina L., Incarbone R., Reitano M., et al. Candida colonization in patients with esophageal disease: a prospective clinical study. Dis Esophagus 2003;16:70-2.
23. Buchacz K., Patel P., Taylor M., et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS 2004;18:2075-9.
24. Day J.H., Grant A.D., Fielding K.L., et al Does tuberculosis increase HIV load? J Infect Dis 2004;190:1677-84.
25. Jones L.E., Perelson A.S. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol 2005;67:1227-51.
26. Gottfredsson M., Cox G.M., Indridason O.S., et al. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis 1999;180:534-7.
27. Murri R., Lepri A.C., Cicconi P., et al. ICoNA Study Group. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naïve patients study. J Acquit Immune Defic Syndr 2006;41:23-30.
28. Seage G.R. 3rd Losina E., Goldie S.J., et al. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 cell counts to chronic mortality. J Acquir Immune Defic Syndr 2002;30:421-8.
29. Manfredi R., Calza L., Chiodo F. Three to seven concurrent AIDS-defining disorders at first hospitalization of AIDS presenters as an unexpected emerging feature during the era of highly active antiretroviral therapy. AIDS 2002;16:2356-8.
30. Manfredi R., Calza L., Chiodo F. Dual Candida albicans and Cryptococcus neoformans fungaemia in an AIDS presenter: a unique disease association in the highly active antiretroviral therapy (HAART) era. J Med Microbiol 2002;51:1135-7.
31. Manfredi R., Fulgaro C., Legnani G., et al. Emergence of amphotericin B.resistant Cryptococcus laurentii meningoencephalitis shortly after treatment for Cryptococcus neoformans meningitis in a patient with AIDS. AIDS Patient Care STDs 2006;20:227-32.
32. Stone S.F., Price P., French M.A. Immune restoration disease: a consequence of dysregulated immune responses after HAART. Curr HIV Res 2004;2:235-42.
33. Manfredi R., Pieri F., Piled S.A., Chiodo F. The changing face of AIDS-related opportunism; cryptococcosis in the highly active antiretoviral therapy (HAART era. Case reports and literature review. Mycopathologia 1999;148:73-8.
34. Vazquez J.A. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials 2000; 1:47-59.
35. Dinubile M.J., Upinacci R.J., Berman R.S., Sable C.A. Response and relapse rates of Candida esophagitis in HIV-infected patients treated with caspofungin. AIDS Res Hum Retroviruses 2002;18:903-8.
36. Manfredi R., Mastroianni A., Coronado O.V., Chiodo F. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection Arch Intern Med 1997;157:64-9.
37. Bozzette S.A. Fluconazole prophylaxis in HIV, disease, revisited. Clin Infect Dis 2005;41:1481-2.
38. Goldman M., Cloud GA., Wade K.D., et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005;41:1473-80.